melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The positive expression of HER4 was correlated with the prognosis of SNMMM patients (P<0.05).
|
29309357 |
2018 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we want to share our experience regarding major problems associated with FFPE DNA used for PCR-based sequencing as illustrated by the mutational analysis of ERBB4 in melanoma.
|
28314930 |
2017 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
At the same time, high throughput sequencing studies of melanoma unraveled a series of new treatment candidates for future treatment approaches such as ERBB4, GRIN2A, GRM3, and RAC1.
|
25654738 |
2015 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results further emphasize the role of HER4 as an important oncogene in malignant melanoma and point to HER4 as a possible drug target in this disease.
|
24366194 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This sequencing technique has successfully been applied within a clinical trial selecting patients with ERBB4-mutant melanoma for lapatinib treatment.
|
24258993 |
2014 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Malignant transformation of melanomas is accompanied by loss of KIT and acquisition of EPO-R and ErbB4, both of which are co-expressed with NGF-R and PD-1 in distinct subfractions of melanoma cells.
|
24489649 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF.
|
24628946 |
2014 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that ERBB4 mutations may play a limited role in melanomas in China; therefore, targeting the ERBB4 mutation in melanoma patients from southern China may not be a promising strategy.
|
23237222 |
2013 |
AMYOTROPHIC LATERAL SCLEROSIS 19
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
|
24119685 |
2013 |
AMYOTROPHIC LATERAL SCLEROSIS 19
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
|
24119685 |
2013 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ligand-mediated activation of ErbB3 and ErbB4 is implicated in the pathogenesis of several human malignancies including cancer of the ovary and melanoma.
|
22856597 |
2012 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gaining further understanding into the oncogenic mechanism of Erbb4 may not only help in the development of targeted therapy in melanoma patients but might accelerate the acceptance of a novel taxonomy of cancer which is based on the genomic perturbations in cancer genes and cancer gene families and their response to targeted agents.
|
20404484 |
2010 |
melanoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.
|
19718025 |
2009 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas.
|
19718025 |
2009 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
|
19800573 |
2009 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.
|
19718025 |
2009 |
melanoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
AMYOTROPHIC LATERAL SCLEROSIS 19
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
AMYOTROPHIC LATERAL SCLEROSIS 19
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
AMYOTROPHIC LATERAL SCLEROSIS 19
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study has implications that miR-141 as well as its target, ERBB4, as a potential target for treating trastuzumab-resistant breast cancers.
|
30746756 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer.
|
31139328 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer.
|
31139328 |
2019 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4.
|
30746756 |
2019 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MED1 mediates induction of cell proliferation and migration and the genes associated with it (JUN, FOS, EGFR, VEGF, MMP1, and ERBB4) in breast cancer, which is abrogated when used together with miR-191-inhibition.
|
30087366 |
2018 |